{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:47:48Z","timestamp":1788493668828,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The clinical application of targeted anti-programmed cell death protein 1 (PD-1) therapy has significantly improved the prognosis of patients with various advanced malignancies. However, life-threatening immune-related adverse events remain problematic, including rare but highly lethal myocarditis. Bidirectional ventricular tachycardia (BVT) is a rare but dangerous form of ventricular arrhythmia. If immune checkpoint inhibitor (ICI)\u2013associated myocarditis is complicated with BVT, patients face an extremely high risk of mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>The first case was a 45-year-old male with advanced intrahepatic cholangiocarcinoma who experienced sudden chest tightness after receiving 11 cycles of camrelizumab. Test results showed significantly elevated myocardial injury markers, and electrocardiography (ECG) indicated BVT; cardiac magnetic resonance imaging findings were consistent with acute myocarditis. A diagnosis of PD-1 inhibitor\u2013associated myocarditis complicated with BVT was considered. Following immunotherapy discontinuation, the patient was treated with steroid therapy, antiarrhythmic drugs, and electrical cardioversion. This led to marked improvements in ICI-associated myocarditis, BVT resolution, and favorable outcomes. The second case was a 34-year-old female patient with type B1 thymoma who experienced sudden chest tightness, shortness of breath, and fatigue after receiving one second-line cycle of sintilimab. Significantly elevated myocardial injury markers were observed, and ECG findings indicated BVT. The patient was diagnosed with PD-1 inhibitor\u2013associated myocarditis complicated with BVT. However, the patient was in critical condition. Despite receiving supportive therapies, including steroid therapy, antiarrhythmic drugs, electrical cardioversion, invasive mechanical ventilation, and extracorporeal membrane oxygenation, the patient\u2019s condition deteriorated rapidly, ultimately leading to death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These two cases demonstrate that although the incidence of malignant arrhythmias such as BVT in ICI-associated myocarditis is low, the risk of sudden death remains extremely high. Therefore, we consider dynamic monitoring of myocardial injury markers and ECG in patients with ICI\u2212associated myocarditis. Additionally, our observations suggest that steroid therapy is a crucial treatment method for patients with ICI-associated myocarditis complicated with BVT. This report adds to the growing body of evidence indicating that BVT is an important yet previously infrequently described ECG manifestation of severe cardiotoxicity associated with ICIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1832047","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:04:34Z","timestamp":1779689074000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Two cases of PD-1 inhibitor\u2013associated myocarditis with bidirectional ventricular tachycardia"],"prefix":"10.3389","volume":"17","author":[{"given":"Xianglin","family":"Lian","sequence":"first","affiliation":[{"name":"Department of Cardiac and Pulmonary Function, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)","place":["Changde, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuoni","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiac Electrophysiology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City)","place":["Changde, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology","volume":"4","author":"Tan","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjon.2024.100598","article-title":"Relevance of surveillance manual for the early detection of immune checkpoint inhibitor-induced myocarditis: a case series","volume":"11","author":"Oyakawa","year":"2024","journal-title":"Asia-Pac J Oncol Nurs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2025.08.004","article-title":"Troponin surveillance in patients receiving immune checkpoint inhibitors","volume":"7","author":"Ostos-Mendoza","year":"2025","journal-title":"JACC CardioOncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/jci145186","article-title":"Immune checkpoint inhibitor\u2013associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.22114\/ajem.v0i0.287","article-title":"Bidirectional ventricular tachycardia in a women with dilated cardiomyopathy: a case report","volume":"4","author":"Norwood","year":"2019","journal-title":"Adv J Emerg Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","article-title":"Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms","volume":"33","author":"Champion","year":"2020","journal-title":"Mod Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.121.055816","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.029211","article-title":"Diagnostic value of the International Society of Cardio\u2010Oncology definition for suspected immune checkpoint inhibitor\u2013associated myocarditis","volume":"12","author":"Deharo","year":"2023","journal-title":"JAHA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00715-5","article-title":"Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart","volume":"24","author":"Munir","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1093\/eurheartj\/ehab219","article-title":"Slow bidirectional ventricular tachycardia as a manifestation of immune checkpoint inhibitor myocarditis","volume":"42","author":"Alhumaid","year":"2021","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/vhrm.s274857","article-title":"Bidirectional ventricular tachycardia: challenges and solutions","volume":"18","author":"Almarzuqi","year":"2022","journal-title":"Vasc Health Risk Manag"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000543593","article-title":"Endomyocardial biopsy: short- and long-term safety in myocarditis patients","volume":"151","author":"Li","year":"2026","journal-title":"Cardiology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jacc.2024.10.080","article-title":"2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis: a report of the American College of Cardiology solution set oversight committee","volume":"85","author":"Drazner","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.47.6.1260","article-title":"Infra-His bundle origin of bidirectional tachycardia","volume":"47","author":"Cohen","year":"1973","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.hrthm.2010.11.038","article-title":"Bidirectional ventricular tachycardia: ping pong in the His\u2013Purkinje system","volume":"8","author":"Baher","year":"2011","journal-title":"Heart Rhythm"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1253\/circj.72.1373","article-title":"Bidirectional ventricular tachycardia caused by a reentrant mechanism with left bundle branch block configuration on electrocardiography","volume":"72","author":"Ueda-Tatsumoto","year":"2008","journal-title":"Circ J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/circep.115.002886","article-title":"Unusual incessant ventricular tachycardia: what is the underlying cause and the possible mechanism","volume":"8","author":"Shenthar","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.121.058936","article-title":"Rare case of wide QRS tachycardia after sintilimab treatment for lung cancer","volume":"145","author":"Tang","year":"2022","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/anec.70002","article-title":"Rare presentation of wide QRS tachycardia in a patient in their 40s","volume":"29","author":"Li","year":"2024","journal-title":"Noninvasive Electrocardiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2025.105543","article-title":"Successful use of ruxolitinib for steroid-refractory immune checkpoint inhibitor\u2013associated myocarditis","volume":"30","author":"Vockenhuber","year":"2025","journal-title":"JACC Case Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2019-thym-12","article-title":"Immunotherapy for thymoma","volume":"12","author":"Jakopovic","year":"2020","journal-title":"J Thorac Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2022.07.009","article-title":"Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors","volume":"81","author":"Furukawa","year":"2023","journal-title":"J Cardiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.07.002","article-title":"Steroids in immune checkpoint inhibitor myocarditis","volume":"6","author":"Palaskas","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer \u2013 a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio\u2010Oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.11.005","article-title":"Immune checkpoint inhibitor myocarditis treatment strategies and future directions","volume":"4","author":"Moslehi","year":"2022","journal-title":"JACC CardioOncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1832047\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:04:37Z","timestamp":1779689077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1832047\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1832047"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1832047","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1832047"}}